Tumor progression: a brief historical perspective
Introduction
This paper is a brief review of our developing knowledge and understanding of the phenomenon of tumor progression, with emphasis on areas of personal interest during a career of more than four decades in cancer research.
The biology of tumor progression will be summarized, including comment on evasion of host immunity. I will then note the contributions of cytogenetics in the 1960s and 1970s to the concept of ‘clonal evolution’ in tumors as a basis for understanding tumor progression. Finally, I will consider superficially the enormous amount of emerging evidence in the 1980s and 1990s concerning the specific genes involved in this process in different tumors, the multiple complex pathways in which the products of these genes are important, and the remarkable clinical implications of these findings.
Section snippets
The biology of tumor progression
It has been recognized for more than a century that most tumors tend to become more aggressive in clinical behavior and more ‘malignant’ in their characteristics over time, although this time course may be quite variable. This phenomenon has been termed ‘tumor progression’, and Foulds is generally credited with first pointing out, in the 1950s, that the process appears to develop in a stepwise fashion through qualitatively different stages.1 Other workers, both before and after, have also
Cytogenetics of tumor progression
My own studies relevant to the initiation and progression of tumors began in the 1960s and 1970s as I became involved in cytogenetic studies of human leukemias. In 1960, I described, with David Hungerford, an abnormal small chromosome in the cells of chronic myelogenous leukemia (CML).17 Subsequently called the Philadelphia (Ph) chromosome, this abnormality was present in essentially every typical case of CML, indicating that it was an important contributor to the pathogenesis of the disease.
Molecular genetics of tumor progression
Through the 1980s and 1990s, increasingly sophisticated methods for isolating and characterizing specific genes and their products greatly extended our understanding of tumor progression, including the remarkable complexity of this phenomenon. In general, the clonal evolution model has been widely confirmed at the molecular level, with the recognition that at least three major types of genes are involved in the full development of common human cancers.
The first group of genes, which has been
Conclusion
Thus, over the past four decades, the biomedical community has acquired an increasing understanding of the phenomenon of tumor progression, including escape from immune regulation. The concept of clonal evolution, with sequential genetic alterations, has been extensively confirmed as the basis for the clinical and biological aspects of tumor progression. It has also become clear that the genes involved cover a variety of functions, and that in most instances the genes are different in one type
References (36)
- et al.
The hallmarks of cancer
Cell
(2000) - et al.
The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells
Cell
(1993) - et al.
Chromosome abnormalities in malignant hematologic diseases
Adv. Cancer Res.
(1982) - et al.
Karyotypic evolution in Ph-positive myeloid leukemia in relation to management and disease progression
Cancer Genet. Cytogenet.
(1985) Gytogenetics of preleukemia
Cancer Genet. Cytogenet.
(1982)- et al.
A survey of telomerase activity in human cancer
Eur. J. Cancer
(1997) Tumor progression
Cancer Res.
(1957)Critical factors in the biology of human cancer metastasis: twenty-eighth GHA clowes memorial award lecture
Cancer Res.
(1990)- Folkman J (1997) Tumor angiogenesis, in Cancer Medicine, 4th edn (Holland JF et al., eds) pp. 181–193. Williams and...
Tumor progression and metastasis
Carcinogenesis
(2000)
Designing therapies that target tumor blood vessels
Science
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation
Science
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Nature
Apoptosis and carcinogenesis
Eur. J. Cell Biol.
The concept of immunologic surveillance
Prog. Exp. Tumor Res.
Tumor immunology
J. Am. Med. Assn.
Cited by (106)
Chemotherapeutics
2023, Pharmacognosy: Fundamentals, Applications, and Strategies, Second EditionPrevention of carcinogenesis and metastasis by Artemisinin-type drugs
2018, Cancer LettersReview of controversies in management of non-benign meningioma
2016, Journal of Clinical NeuroscienceIntracellular signaling mechanisms in thyroid cancer
2016, Cirugia y CirujanosCancer modelling in the NGS era - Part I: Emerging technology and initial modelling
2015, Critical Reviews in Oncology/HematologyCitation Excerpt :The pioneering work of Peter Nowell in Science in 1976 (ITH model 1, Table 1) established the basis of cancer clonal theory [277], by hypothesizing a mechanism of monoclonal or polyclonal expansions dominated by Darwinian selection. Individual clones can be swept away by competing clones or by environmental forces including therapeutic intervention [278]. In this Darwinian vision, the emergence of a new competing clone follows a pattern of linear or branched evolution, as it is being elucidated today.